{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.93","upperLimit":"9.97","value":"7.00"},{"groupId":"OG001","lowerLimit":"6.94","upperLimit":"11.0","value":"8.00"},{"groupId":"OG002","lowerLimit":"3.93","upperLimit":"11.0","value":"7.00"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"13"}],"units":"Participants"}],"dispersionType":"Full Range","groups":[{"description":"Participants received SC elranatamab with a priming regimen of 12 mg on C1D1 and 32 mg on C1D4 followed by 76 mg QW thereafter starting from Cycle 1 Day 8.","id":"OG000","title":"Phase 1b"},{"description":"Participants received SC elranatamab with a priming regimen of 12 mg on C1D1 and 32 mg on C1D4 followed by 76 mg QW thereafter starting from Cycle 1 Day 8.","id":"OG001","title":"Phase 2"},{"description":"Participants received SC elranatamab with a priming regimen of 12 mg on C1D1 and 32 mg on C1D4 followed by 76 mg QW thereafter starting from Cycle 1 Day 8.","id":"OG002","title":"Phase 1b + Phase 2"}],"paramType":"MEDIAN","populationDescription":"PK parameter analysis set included all participants enrolled and treated who had at least 1 of the PK parameters of primary interest in the single dose and/or multiple-dose PK part. Here, \"Number of Participants Analyzed\" signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Cycle 1: Pre-dose, 6 hours post-dose on Day 1, 24, 48 hours post-dose, Day 4: pre-dose, 24 hour post-dose, Day 8 pre-dose, 6 hours post-dose, Day 15,22: pre-dose, Cycles 2, 3 ,4,7: pre-dose (1 cycle =28 days)","title":"Time To Maximum Serum Concentration (Tmax) of Free Elranatamab","type":"SECONDARY","unitOfMeasure":"Days"}